Management of Treatment-Resistant Depression with Comorbid ADHD
Addressing Treatment-Resistant Depression
- The American Academy of Family Physicians recommends tapering paroxetine over 10-14 days to limit withdrawal symptoms in patients with treatment-resistant depression 1
- The STAR*D trial provides evidence that 1 in 4 patients became symptom-free after switching medications, with no difference among bupropion, sertraline, and venlafaxine, for patients with treatment-resistant depression 2, 3, 4
- Switching to bupropion sustained-release is recommended as first choice because it has dual benefits: antidepressant efficacy AND documented benefit for ADHD symptoms, according to the Journal of the American Academy of Child and Adolescent Psychiatry 5, 6, 7
- Alternative options include venlafaxine extended-release or sertraline if bupropion is contraindicated, as shown in the Annals of Internal Medicine 2, 3, 4
Addressing ADHD Symptoms
- The American Academy of Child and Adolescent Psychiatry guidelines recommend starting with methylphenidate 5-20mg three times daily OR dextroamphetamine 5mg three times daily to 20mg twice daily for ADHD treatment 5, 6, 7
- Stimulants have rapid onset, allowing quick assessment of ADHD symptom response, and reduction in ADHD-related morbidity can substantially impact depressive symptoms, according to the Journal of the American Academy of Child and Adolescent Psychiatry 5, 6, 7
- The American Academy of Child and Adolescent Psychiatry recommends screening carefully for substance abuse disorder before prescribing stimulants, as this is a major contraindication 5, 7
Treatment Algorithm
- The American Academy of Family Physicians recommends tapering paroxetine over 10-14 days and starting bupropion SR 150mg daily, increase to 150mg BID after 3 days, for patients with treatment-resistant depression and comorbid ADHD 1
- The Journal of the American Academy of Child and Adolescent Psychiatry recommends initiating methylphenidate 5mg three times daily OR dextroamphetamine 5mg twice daily and titrating stimulant dose based on response and tolerability 5, 7